Weiguang Biotech: Subcutaneous Human Immunoglobulin Receives Clinical Trial Approval

Weigao Biology announced that it recently received the “Clinical Trial Approval Notice” issued by the National Medical Products Administration (Notice Number: 2026LP00795), granting approval for the company’s subcutaneous injection of human immunoglobulin to conduct clinical trials for the treatment of primary immunodeficiency disease (PID).

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin